Bollard Group LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 9.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,414 shares of the company’s stock after acquiring an additional 863 shares during the quarter. Bollard Group LLC’s holdings in Johnson & Johnson were worth $1,354,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the stock. Probity Advisors Inc. lifted its position in Johnson & Johnson by 2.8% in the 3rd quarter. Probity Advisors Inc. now owns 13,891 shares of the company’s stock worth $1,806,000 after buying an additional 384 shares in the last quarter. Van Cleef Asset Management Inc lifted its position in Johnson & Johnson by 1.7% in the 3rd quarter. Van Cleef Asset Management Inc now owns 78,520 shares of the company’s stock worth $10,208,000 after buying an additional 1,285 shares in the last quarter. Northern Capital Management LLC lifted its position in Johnson & Johnson by 10.2% in the 3rd quarter. Northern Capital Management LLC now owns 33,441 shares of the company’s stock worth $4,348,000 after buying an additional 3,090 shares in the last quarter. K.J. Harrison & Partners Inc lifted its position in Johnson & Johnson by 33.2% in the 3rd quarter. K.J. Harrison & Partners Inc now owns 62,011 shares of the company’s stock worth $8,062,000 after buying an additional 15,451 shares in the last quarter. Finally, Parametrica Management Ltd lifted its position in Johnson & Johnson by 57.9% in the 3rd quarter. Parametrica Management Ltd now owns 4,100 shares of the company’s stock worth $533,000 after buying an additional 1,503 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Friday. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $146.42. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market cap of $391,590.00, a price-to-earnings ratio of 25.31, a P/E/G ratio of 2.73 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period last year, the business posted $1.68 EPS. Johnson & Johnson’s revenue was up 10.3% compared to the same quarter last year. equities analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s payout ratio is presently 58.33%.
A number of research firms have issued reports on JNJ. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research note on Monday, September 18th. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Wells Fargo & Co upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $140.00 to $149.00 in a research note on Monday, October 9th. Finally, JPMorgan Chase & Co. lowered shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $145.94.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Bought by Bollard Group LLC” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/johnson-johnson-jnj-shares-bought-by-bollard-group-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.